Jarmo J Pystynen

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Orion-Yhtyma Oy, Orion Corporation, Orion Corporation/orion Pharmaceutica. Active years: 1990-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jarmo J Pystynen. Retrieved from https://idiyas.com/inventor/jarmo-j-pystynen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 7.2

ph-index = 8

Forward Citations = 285(Granted Patents)

Company Filing History:

Orion Corporation/orion Pharmaceutica

patent

Years Active: 1990-2020

Loading Chart...

Areas of Expertise:

Alpha2C Antagonists

COMT Inhibitors

Pharmaceutical Compounds

Heart Failure Treatments

Pyridazinyl Compounds

Catechol Derivatives

Phospholamban Inhibitors

Stunned Myocardium

Heterocyclic Compounds

Thiadiazines

Pentanedione Derivatives

Naphthalene Derivatives

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10774074 - 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists (2020-09-15),

2. 9458128 - Catechol O-methyltransferase activity inhibiting compounds (2016-10-04),

3. 8318785 - Pharmaceutical compounds (2012-11-27),

4. 6951870 - Coumarin derivatives with COMT inhibiting activity (2005-10-04),

5. 6903114 - Derivatives of naphthalene with COMT inhibiting activity (2005-06-07),

6. 6699868 - Pyridazinyl phenyl hydrazones useful against congestive heart failure (2004-03-02),

7. 6265421 - Phospholamban inhibitors and a method for increasing coronary flow (2001-07-24),

8. 6150412 - Catechol derivatives (2000-11-21),

9. 5968959 - Method for the prevention and treatment of stunned myocardium (1999-10-19),

10. 5446194 - Pharmacologically active catechol derivatives (1995-08-29),

11. 5292771 - Substituted .beta.-diketones and their use (1994-03-08),

12. 5283352 - Pharmacologically active compounds, methods for the preparation thereof (1994-02-01),

13. 5185370 - Substituted .beta.-diketones and their use (1993-02-09),

14. 5185332 - Thiadiazines and pharmaceutical compositions thereof as well as method (1993-02-09),

15. 5151420 - Substituted pyridazinones (1992-09-29),

Title: Jarmo J Pystynen: Innovator in Pharmaceutical Technologies

Introduction

Jarmo J Pystynen, based in Espoo, Finland, is a distinguished inventor with an impressive portfolio of 20 patents. His work primarily focuses on the development of pharmaceutical compounds that can aid in treating various diseases affecting the central and peripheral nervous systems.

Latest Patents

Among his latest innovations are noteworthy patents such as "2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists." This patent describes compounds designed to exhibit alpha2C antagonistic activity, proving beneficial in treating conditions that affect the nervous system. Another significant patent is for "Catechol O-methyltransferase activity inhibiting compounds." These novel compounds demonstrate COMT enzyme inhibiting activity and are valuable for pharmaceutical applications aimed at improving patient outcomes.

Career Highlights

Throughout his career, Jarmo has made substantial contributions to the pharmaceutical industry, particularly during his tenure at Orion-yhtyma Oy and Orion Corporation. His innovative approach has propelled advancements in drug development.

Collaborations

He has collaborated with esteemed colleagues such as Erkki J Honkanen and Aino K Pippuri, further enhancing the collaborative environment necessary for groundbreaking research and development.

Conclusion

Jarmo J Pystynen stands out as a prominent inventor in the pharmaceutical field. His dedication to creating effective treatments is evident through his numerous patents and collaborative efforts, making significant contributions to medical innovation and research.

Profile summary based on public USPTO records.